Outcome of patients treated with docetaxel versus paclitaxel in a non-randomized phase IV trial of first-line taxane/trastuzumab therapy in patients with HER2+metastatic breast cancer (MBC)

被引：0
|
作者：
Reddy, JC [1 ]
Barker, C [1 ]
Lim, D [1 ]
Klein, PM [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2004年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [41] Association of PTEN Loss and PIK3CA Mutations on Outcome in HER2+Metastatic Breast Cancer Patients Treated with First-Line Lapatinib Plus Paclitaxel or Paclitaxel Alone
    Xu, B.
    Guan, Z-Z
    Shen, Z-Z
    Tong, Z-S
    Jiang, Z-F
    Yang, J-I
    DeSilvio, M.
    Leigh, M.
    Ellis, C.
    CANCER RESEARCH, 2011, 71
  • [42] Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer
    Burris, H
    Yardley, D
    Jones, S
    Houston, G
    Broome, C
    Thompson, D
    Greco, FA
    White, M
    Hainsworth, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1621 - 1629
  • [43] A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Xu, L
    Song, S
    Zhu, J
    Luo, R
    Li, L
    Jiao, S
    Pan, H
    Tao, M
    Su, Y
    Liu, D
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S94
  • [44] A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (PTS) with HER2-positive metastatic breast cancer (MBC)
    Xu, Ligong
    Song, Santai
    Zhu, Jianxin
    Luo, Rongcheng
    Li, Lejing
    Jiao, Sunchang
    Chen, Li
    Tao, Min
    Su, Yongqian
    Liu, Duanqi
    ANNALS OF ONCOLOGY, 2006, 17 : 76 - 77
  • [45] A Phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER-2-positive metastatic breast cancer (MBC)
    Xu, L.
    Song, S.
    Zhu, J.
    Lu, R.
    Li, L.
    Jiao, S.
    Pan, H.
    Tao, M.
    Su, Y.
    Liu, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 125 - 125
  • [46] AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
    Gianni, Luca
    Romieu, Gilles H.
    Lichinitser, Michail
    Serrano, Sergio V.
    Mansutti, Mauro
    Pivot, Xavier
    Mariani, Paola
    Andre, Fabrice
    Chan, Arlene
    Lipatov, Oleg
    Chan, Stephen
    Wardley, Andrew
    Greil, Richard
    Moore, Nicola
    Prot, Sylvie
    Pallaud, Celine
    Semiglazov, Vladimir
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) : 1719 - +
  • [47] AVEREL: a randomized Phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer
    不详
    BREAST CANCER MANAGEMENT, 2013, 2 (04) : 274 - 274
  • [48] Phase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancer.
    Ciardiello, F
    Troiani, T
    Caputo, F
    de Laurentiis, M
    Tortora, G
    Palmieri, G
    de Vita, F
    Colantuoni, G
    de Placido, S
    Bianco, AR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 211S - 211S
  • [49] Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial
    Noortje Verschoor
    Manouk K. Bos
    Ingeborg E. de Kruijff
    Mai N. Van
    Jaco Kraan
    Jan C. Drooger
    Johanna M. Zuetenhorst
    Saskia M. Wilting
    Stefan Sleijfer
    Agnes Jager
    John W. M. Martens
    Breast Cancer Research and Treatment, 2024, 205 : 87 - 95
  • [50] Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial
    Verschoor, Noortje
    Bos, Manouk K.
    de Kruijff, Ingeborg E.
    Van, Mai N.
    Kraan, Jaco
    Drooger, Jan C.
    Zuetenhorst, Johanna M.
    Wilting, Saskia M.
    Sleijfer, Stefan
    Jager, Agnes
    Martens, John W. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 205 (01) : 87 - 95
12345